<DOC>
	<DOCNO>NCT02087917</DOCNO>
	<brief_summary>To determine efficacy HS-25 ( 5 , 10 , 20 30 mg ) reduce low density lipoprotein-cholesterol ( LDL-C ) level 4-week period treatment adult primary hypercholesterolemia .</brief_summary>
	<brief_title>A 4-week , Randomized , Placebo-Controlled , Double-Blind , Efficacy Safety Study HS-25 Adults With Primary Hypercholesterolemia</brief_title>
	<detailed_description>This 4-week , randomize , double-blind , placebo-controlled study design assess effect cholesterol absorption inhibitor HS-25 LDL-C level adult untreated LDL-C level range 130-189 mg/dL fast triglyceride level &lt; 350 mg/dL . Eligibility restrict 18-65 year old men woman use highly effective birth control method childbearing potential . Patients diabetes , history myocardial infarction clinical evidence atherosclerotic vascular disease eligible participation study .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Men , woman use highly effective birth control method childbearing potential , 18 65 year age Visit 1 ( screen visit ) . LDLC 130 189 mg/dL ( inclusive ) cholesterol lower diet lipid modify drug treatment least 6 week . A qualify LDLC value must obtain begin end placebo runin ( Visit 2 Visit 3 ) Visit 3 value must within 15 % value Visit 2 , high low ; average qualify value must range 130 189 mg/dL ( inclusive ) inclusion study . TG ≤ 350 mg/dL cholesterol lower diet lipid modify drug treatment least 6 week TG level must ≤ 350 mg/dL Visit 2 Visit 3 Compliance 80 % 120 % assign study drug regimen 2 week placebo runin phase . Women pregnant breast feeding . History stroke , myocardial infarction , unstable angina , heart failure arterial revascularization procedure ( eg , carotid , coronary , aorta , peripheral arterial ) . History diabetes glycosylated hemoglobin ( HbA1c ) &gt; 6.5 . History moderate severe lactose intolerance ( eg , unable drink glass milk ) . History hospitalization treatment major psychiatric disorder . History drug alcohol abuse define Diagnostic Statistical Manual ( DSM5 ) within prior 12 month . History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week men ( 1 drink = 5 ounce wine 12 ounce beer 1.5 ounce hard liquor ) within 6 month prior screen . Hospitalization duration &gt; 24 hour reason within prior 3 month , opinion investigator , may affect adherence study procedure . History positive test human immunodeficiency virus , hepatitis B hepatitis C. History cancer exception welltreated basal cell squamous cell carcinoma skin , insitu cervical carcinoma . Presence condition , opinion investigator , likely compromise completion trial best interest subject . History intolerance ezetimibe . Participation prior study HS 25 . Participation study investigational drug device within prior 3 month unless subject documentation placebo administration placebocontrolled drug treatment trial . Treatment fibric acid derivative ( eg , fenofibrate , gemfibrozil ) , probucol , warfarin , systemic corticosteroid , cyclosporine immunosuppressant agent within prior 12 week . Anticipated need frequent use acetaminophen ( &gt; 2 gm/day , require &gt; 4x/week ) . Vitamins , herbal dietary supplement must discontinue screen unless subject longterm daily regimen agree continue regimen study . Alanine aminotransferase ( ALT ) &gt; 1.0 × upper limit normal ( ULN ) Visit 1 , Visit 2 Visit 3 . Aspartate aminotransferase ( AST ) &gt; 1.0 × ULN Visit 1 , Visit 2 Visit 3 . Unexplained ( due exercise strenuous activity ) creatinine kinase increase &gt; 2 × ULN Visit 1 , Visit 2 Visit 3 . Estimated glomerular filtration rate ( Modification Diet Renal Disease ) &lt; 60 mL/min/1.73m2 Visit 1 , Visit 2 Visit 3 . Thyroid stimulate hormone outside normal range . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical disease ( eg , infectious disease ) must enrol . Any laboratory abnormality consider investigator clinically significant . Any subject electrocardiogram ( ECG ) QTc interval ≥ 450 msec , abnormality consider investigator clinically significant end placebo runin ( Visit 3 ) enrol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>hypercholesterolemia</keyword>
	<keyword>cholesterol absorption inhibitor</keyword>
	<keyword>placebo-controlled trial</keyword>
</DOC>